Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e20529
Abstract: e20529Background: Exclusion from cancer clinical trials is common for patients taking QTc-interval prolonging drugs. To estimate the potential impact on accrual, we determined the prevalence of QTc... read more here.
Keywords: prolonging medications; clinical trials; cancer; qtc prolonging ... See more keywords